Mirae Asset Capital Life Science, a Boston, MA- and San Francisco, CA-based venture capital firm investing in private biotechnology companies, has emerged from stealth with its inaugural $50m fund.
Mirae Asset Capital Life Science Inception I, LP, is supported by a diverse global investor base comprised of Limited Partners within the Mirae Asset Financial Group.
The firm plans to invest the fund in private biotechnology companies from seed to series C with a primary focus on therapeutics (modality agnostic) but will remain opportunistic to diagnostics and AI/ML tools for drug discovery and protein engineering.
The core sectors of interest include: Oncology, Immunology, Cardiovascular/Metabolic Disease, CNS/Ophthalmology, and Genetic Disease.
The firm can lead or follow deals, intends to support its portfolio companies through exit, and seeks to be an active investor at the board level.
First check size can vary but will not exceed $10m except with co-investment with other Mirae Asset affiliates. The firm has investment team members in Boston and San Francisco while receiving legal and administrative support from its New York office.
The firm is led by Managing Director Naveen M. Krishnan, MD, MPhil., who has nearly 20 years of experience in healthcare with nearly a decade of clinical/medical training and a decade of biotech experience across basic science drug discovery (Harvard/Broad Institute/MGH), operating experience building public and private companies, and as a venture capital investor at Bayer where he sat on the board of seven companies and led or supported over 20 deals.
Dr. Krishnan obtained a BS in Brain and Cognitive Sciences from MIT, an MD from Dartmouth (Albert Schweitzer Fellow), clinical residency training based out of Georgetown University Hospital, and a Master’s degree in Public Health (MPhil) from the University of Cambridge as a Gates Cambridge Scholar.
Mirae Asset Capital Life Science is the sole U.S. affiliate investing in life science within the Mirae Asset Financial Group, a global financial group overseeing nearly $600bn AUM across a diversified platform, who has been making investments in life science over the past decade. Over the past decade, Mirae Asset has invested in more than 100 biotech companies worldwide, including BioNTech and Vividion.